The global ocular pain retrobulbar treatment market size was valued at USD 5.99 million in 2024 and is expected to reach USD 10.15 million by 2032, at a CAGR of 6.80% during the forecast period
The market growth is largely fueled by the rising prevalence of ophthalmic disorders, increasing surgical volumes such as cataract and glaucoma procedures, and the growing use of regional anesthesia techniques in ophthalmology
Furthermore, rising demand for effective pain management in blind painful eyes and perioperative care, coupled with advancements in anesthetic and neurolytic agents, is establishing retrobulbar treatments as a critical therapeutic approach. These converging factors are accelerating the adoption of ocular pain management solutions, thereby significantly boosting the industry’s growth